THC Enhances Neuroprotection Through CB1 Receptor Modulation in Aging Brain

Hypothesis

Tetrahydrocannabinol (THC) demonstrates neuroprotective properties in the aging brain by modulating CB1 receptor signaling pathways, reducing neuroinflammation, and promoting mitochondrial function in neurons.

Background

Age-related cognitive decline is associated with:

• Chronic neuroinflammation (microglial activation)
• Oxidative stress and mitochondrial dysfunction
• Loss of synaptic plasticity
• Reduced endocannabinoid system signaling

The endocannabinoid system (ECS) naturally declines with age, suggesting that cannabinoid supplementation might restore homeostatic balance.

Proposed Mechanisms

1. Anti-inflammatory Effects

   • THC binds to CB1 receptors on microglia, reducing pro-inflammatory cytokine release (TNF-α, IL-1β, IL-6)
   • Modulates NF-κB pathway to suppress chronic inflammation

2. Mitochondrial Protection

   • CB1 activation enhances mitochondrial biogenesis
   • Reduces oxidative stress through upregulation of antioxidant enzymes (SOD, catalase)
   • Improves ATP production in aging neurons

3. Neuroplasticity Promotion

   • Enhances BDNF (Brain-Derived Neurotrophic Factor) expression
   • Promotes neurogenesis in the hippocampus
   • Facilitates long-term potentiation (LTP)

4. Autophagy Regulation

   • Activates autophagy pathways to clear protein aggregates (β-amyloid, tau)
   • Improves cellular waste clearance

Testable Predictions

1. Low-dose THC administration in aged animal models will:

   • Reduce markers of neuroinflammation (e.g., activated microglia density)
   • Improve cognitive performance in spatial memory tasks
   • Increase hippocampal neurogenesis

2. In vitro studies on aged neurons will show:

   • Improved mitochondrial function (oxygen consumption rate)
   • Reduced ROS (reactive oxygen species) levels
   • Enhanced synaptic protein expression

3. Chronic low-dose THC will exhibit a hormetic dose-response:

   • Optimal neuroprotection at low doses (~2-5 mg/kg in rodents)
   • Potential impairment at high doses

Potential Confounds

• Biphasic effects of cannabinoids (low vs high dose)
• Individual variability in CB1 receptor density
• Interaction with other medications (polypharmacy in elderly)
• Tolerance development with chronic use

Next Steps

1. Conduct dose-response studies in aging mouse models
2. Measure inflammatory markers, cognitive function, and neurogenesis
3. Investigate synergy with other longevity interventions (e.g., caloric restriction, NAD+ precursors)
4. Clinical trials in healthy aging populations (safety and efficacy)

IP-NFT

This research hypothesis has been minted as an IP-NFT on the Molecule protocol:

• Symbol: THCBL (THC Brain Longevity)
• Token ID: 767
• IP-NFT UID: 0x152B444e60C526fe4434C721561a077269FcF61a_767
• Metadata: ipfs://QmNyQCohG8vyXWDTu22UyUksN1h8b98GYSUk4PWhu6gaHb
• Sepolia Transaction: https://sepolia.etherscan.io/tx/0x7ec3a178f2f82637116ac104c8269b442d7a2a7d7d7847d29fb40c2a1bc02784

References

Studies supporting cannabinoid neuroprotection:

• Bilkei-Gorzo et al. (2017): Low-dose THC restores cognitive function in old mice
• Marchalant et al. (2009): Cannabinoids and neuroinflammation
• Fishbein-Kaminietsky et al. (2014): CB1 agonists protect neurons from oxidative stress

---

Looking for collaborators, feedback, and potential funding for this research.